Extrakorporale Leberunterstützungsverfahren beim Leberversagen

Zusammenfassung

Als extrakorporale Leberunterstützungstherapie werden die zellfreien – artifiziellen Verfahren (artificial liver support, ALS) von den zellbasierten – bioartifiziellen Verfahren (bioartificial liver support, BLS) unterschieden. Die artifiziellen Verfahren, verbessern durch die gleichzeitige Entfernung von proteingebundenen und wasserlöslichen Substanzen biochemische Parameter des Leberversagens. Hierbei gehört die MARS-Therapie zu dem am besten untersuchten Verfahren, wobei ein Effekt bzgl. der Symptomkontrolle der hepatischen Enzephalopathie (HE), dem hepatorenalen Syndrom (HRS) oder der Hyperbilirubinämie nachgewiesen werden konnte. Ein genereller Überlebensvorteil jedweder Leberdialyse beim Leberversagen lässt sich jedoch nicht bzw. nur in Metaanalysen oder für Subgruppen zeigen. Es existieren keine prospektiv randomisierten Studien zur Therapie des Leberversagens durch Intoxikationen. Mehrere Fallserien berichten jedoch von positiven Therapieeffekten unter Verwendung des MARS-Systems, insbesondere bei Knollenblätterpilzvergiftungen oder Paracetamolintoxikationen. Beim akuten Leberversagen (ALF) konnten Studien unter Verwendung der BLS keinen Überlebensvorteil zeigen. Unter Verwendung von ALS-Systemen konnte in Patientensubgruppen nach mehreren konsekutiven MARS-Therapien ein positiver Effekt auf die Mortalität erreicht werden. Die bislang einzige prospektiv, randomisierte Studie mit signifikantem Überlebensvorteil verwendete großvolumige Plasmapherese als Therapieverfahren. Offenbar spielen hier immunmodulatorische und hämodynamische Effekte der Therapie eine entscheidende Rolle. Bei Patienten mit akut-auf-chronischem Leberversagen (acute on chronic liver failure, ACLF) und Hyperbilirubinämie ohne weiteres Organversagen (singuläre hepatische Dysfunktion) hat ein BLS-System prognostisch günstige Effekte gezeigt. Sobald jedoch auch andere extrahepatische Organsysteme betroffen sind und ein fortschreitender Übergang ins Multiorganversagen vorliegt, konnte mit dem MARS- bzw. Prometheus-Systems ein Überlebensvorteil erreicht werden. Entscheidend für einen Therapieerfolg ist die genaue Indikationsstellung des jeweiligen Leberdialyseverfahrens bei diesem sehr heterogenen Krankheitsbild. Zukünftige Studien sind nötig, um genauere Patientenselektionskriterien bzgl. des jeweiligen Leberunterstützungsverfahrens zu definieren.

Abstract

Extracorporeal liver support can be classified into cell-free, artificial methods (artificial liver support, ALS) and cell-based bioartificial methods (bioartificial liver support, BLS). ALS improves biochemical parameters of liver failure by the simultaneous removal of protein-bound and water-soluble substances. Here, the MARS therapy belongs to the most studied methods with a proved beneficial effect on hepatic encephalopathy (HE), hepatorenal syndrome (HRS) or hyperbilirubinemia. However, a general survival advantage of any liver support for liver failure has not been shown yet and is restricted to meta-analyses or patient subgroups. There are no prospective randomized studies on the treatment of liver failure by intoxication. However, several case series report positive treatment effects using the MARS system, particularly in mushroom poisoning or acetaminophen intoxication. In acute liver failure (ALF) studies, the usage of BLS showed no survival advantage. Using ALS systems, a positive effect on mortality could be demonstrated in patient subgroups after several consecutive MARS therapies. The first randomized controlled trial demonstrating a survival benefit used large-volume plasmapheresis. Apparently, immunomodulatory and hemodynamic effects of the treatment play a crucial role in this context. In patients with acute-on-chronic liver failure (ACLF) accompanied by hyperbilirubinemia without any further organ failure (singular hepatic dysfunction), prognostic favorable effects by using a BLS system have been shown. However, once other extrahepatic organ systems are affected, indicating a progressive transition to multi-organ failure, a survival advantage could be achieved with the MARS and Prometheus system. Decisive for a successful therapy is the exact indication of the respective liver dialysis procedure for this very heterogeneous disease. Future studies are needed to define more accurate patient selection criteria for each liver support.

Schlüsselwörter

akutes Leberversagen - Akutes-auf-chronisches Leberversagen - extrakorporale Leberunterstützungsverfahren

Key words

acute liver failure - acute-on-chronic liver failure - extracorporeal liver support

^* These authors contributed equally to this work.

• Literatur

• 1 Bernal W. Jalan R. Quaglia A. et al. Acute-on-chronic liver failure. Lancet 2015; 386: 1576-1587
• 2 Bismuth H. Samuel D. Gugenheim J. et al. Emergency liver transplantation for fulminant hepatitis. Ann Intern Med 1987; 107: 337-341
• 3 Germani G. Theocharidou E. Adam R. et al. Liver transplantation for acute liver failure in Europe: outcomes over 20 years from the ELTR database. J Hepatol 2012; 57: 288-296
• 4 Saliba F andSamuel D. Acute liver failure: current trends. J Hepatol 2013; 59: 6-8
• 5 Stockmann HB. Hiemstra CA. Marquet RL. et al. Extracorporeal perfusion for the treatment of acute liver failure. Ann Surg 2000; 231: 460-470
• 6 Karvellas CJ. Bagshaw SM. McDermid RC. et al. A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif 2009; 28: 151-158
• 7 Umgelter A. Lange K. Kornberg A. et al. Orthotopic liver transplantation in critically ill cirrhotic patients with multi-organ failure: a single-center experience. Transplant Proc 2011; 43: 3762-3768
• 8 Stange J. Ramlow W. Mitzner S. et al. Dialysis against a recycled albumin solution enables the removal of albumin-bound toxins. Artif Organs 1993; 17: 809-813
• 9 Stange J. Mitzner SR. Risler T. et al. Molecular adsorbent recycling system (MARS): clinical results of a new membrane-based blood purification system for bioartificial liver support. Artif Organs 1999; 23: 319-330
• 10 Mitzner SR. Stange J. Klammt S. et al. Albumin dialysis using the molecular adsorbent recirculating system. Curr Opin Nephrol Hypertens 2001; 10: 777-783
• 11 Mitzner SR. Stange J. Klammt S. et al. Extracorporeal detoxification using the molecular adsorbent recirculating system for critically ill patients with liver failure. J Am Soc Nephrol 2001; 12 (Suppl. 17) S75-82
• 12 Mitzner SR. Stange J. Klammt S. et al. Albumin dialysis MARS: knowledge from 10 years of clinical investigation. ASAIO J 2009; 55: 498-502
• 13 Laleman W. Wilmer A. Evenepoel P. et al. Effect of the molecular adsorbent recirculating system and Prometheus devices on systemic haemodynamics and vasoactive agents in patients with acute-on-chronic alcoholic liver failure. Crit Care 2006; 10: R108
• 14 Catalina MV. Barrio J. Anaya F. et al. Hepatic and systemic haemodynamic changes after MARS in patients with acute on chronic liver failure. Liver Int 2003; 23 (Suppl. 03) 39-43
• 15 Sen S. Mookerjee RP. Cheshire LM. et al. Albumin dialysis reduces portal pressure acutely in patients with severe alcoholic hepatitis. J Hepatol 2005; 43: 142-148
• 16 Pares A. Deulofeu R. Cisneros L. et al. Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Crit Care 2009; 13: R8
• 17 Hassanein TI. Tofteng F. Brown RS Jr. et al. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology 2007; 46: 1853-1862
• 18 Pares A. Herrera M. Aviles J. et al. Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers. J Hepatol 2010; 53: 307-312
• 19 Leckie P. Tritto G. Mookerjee R. et al. “Out-patient” albumin dialysis for cholestatic patients with intractable pruritus. Aliment Pharmacol Ther 2012; 35: 696-704
• 20 Pares A. Cisneros L. Salmeron JM. et al. Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 2004; 99: 1105-1110
• 21 Bellmann R. Graziadei IW. Feistritzer C. et al. Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis. Liver Transpl 2004; 10: 107-114
• 22 Schachschal G. Morgera S. Kupferling S. et al. MARS dialysis in the state of chronic rejection in a liver transplant recipient. Am J Gastroenterol 2002; 97: 1059-1060
• 23 Falkenhagen D. Strobl W. Vogt G. et al. Fractionated plasma separation and adsorption system: a novel system for blood purification to remove albumin bound substances. Artif Organs 1999; 23: 81-86
• 24 Rifai K. Ernst T. Kretschmer U. et al. Prometheus – a new extracorporeal system for the treatment of liver failure. J Hepatol 2003; 39: 984-990
• 25 Krisper P. Haditsch B. Stauber R. et al. In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. J Hepatol 2005; 43: 451-457
• 26 Evenepoel P. Laleman W. Wilmer A. et al. Prometheus versus molecular adsorbents recirculating system: comparison of efficiency in two different liver detoxification devices. Artif Organs 2006; 30: 276-284
• 27 van Wenum M. Chamuleau RA. van Gulik TM. et al. Bioartificial livers in vitro and in vivo: tailoring biocomponents to the expanding variety of applications. Expert Opin Biol Ther 2014; 14: 1745-1760
• 28 Demetriou AA. Brown RS Jr. Busuttil RW. et al. Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. Ann Surg 2004; 239: 660-667; discussion 667-670
• 29 Ellis AJ. Hughes RD. Wendon JA. et al. Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology 1996; 24: 1446-1451
• 30 Sussman NL. Gislason GT. Conlin CA. et al. The Hepatix extracorporeal liver assist device: initial clinical experience. Artif Organs 1994; 18: 390-396
• 31 Randomized, Open-Label, Multicenter, Controlled, Pivotal Study to Assess Safety and Efficacy of ELAD in Subjects w/AILD. (NCT02612428). ClinicalTrials.gov
• 32 Peszynski P. Stange J. Mitzner S. et al. Removal of Benzodiazepine-like Substances as a Cause of Improvement of Hepatic Encephalopathy during Albumin Dialysis. Z Gastroenterol 2001; 39: 53-53
• 33 Wittebole X andHantson P. Use of the molecular adsorbent recirculating system (MARS) for the management of acute poisoning with or without liver failure. Clin Toxicol (Phila) 2011; 49: 782-793
• 34 Sen S. Ytrebo LM. Rose C. et al. Albumin dialysis: a new therapeutic strategy for intoxication from protein-bound drugs. Intensive Care Med 2004; 30: 496-501
• 35 de Geus H. Mathot R. van der Hoven B. et al. Enhanced paracetamol clearance with molecular adsorbents recirculating system (MARS(R)) in severe autointoxication. Blood Purif 2010; 30: 118-119
• 36 Sorodoc L. Lionte C. Sorodoc V. et al. Is MARS system enough for A. phalloides-induced liver failure treatment? Hum Exp Toxicol 2010; 29: 823-832
• 37 Pillukat M. Schomacher T. Baier P. et al. Early initiation of MARS® dialysis in Amanita phalloides-induced acute liver injury prevents liver transplantation. Ann Hepatol. 2016; 15: 775-787
• 38 Rademacher S. Oppert M. Jorres A. Artificial extracorporeal liver support therapy in patients with severe liver failure. Expert Rev Gastroenterol Hepatol 2011; 5: 591-599
• 39 Antoniades CG. Berry PA. Wendon JA. et al. The importance of immune dysfunction in determining outcome in acute liver failure. J Hepatol 2008; 49: 845-861
• 40 Lee WM. Stravitz RT. Larson AM. Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology 2012; 55: 965-967
• 41 Bernal W andWendon J. Acute liver failure. N Engl J Med 2013; 369: 2525-2534
• 42 O'Grady JG. Gimson AE. O'Brien CJ. et al. Controlled trials of charcoal hemoperfusion and prognostic factors in fulminant hepatic failure. Gastroenterology 1988; 94: 1186-1192
• 43 Kantola T. Koivusalo AM. Hockerstedt K. et al. The effect of molecular adsorbent recirculating system treatment on survival, native liver recovery, and need for liver transplantation in acute liver failure patients. Transpl Int 2008; 21: 857-866
• 44 Camus C. Lavoue S. Gacouin A. et al. Liver transplantation avoided in patients with fulminant hepatic failure who received albumin dialysis with the molecular adsorbent recirculating system while on the waiting list: impact of the duration of therapy. Ther Apher Dial 2009; 13: 549-555
• 45 Camus C. Lavoue S. Gacouin A. et al. Molecular adsorbent recirculating system dialysis in patients with acute liver failure who are assessed for liver transplantation. Intensive Care Med 2006; 32: 1817-1825
• 46 Saliba F. Camus C. Durand F. et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 2013; 159: 522-531
• 47 Novelli G. Rossi M. Ferretti G. et al. Predictive criteria for the outcome of patients with acute liver failure treated with the albumin dialysis molecular adsorbent recirculating system. Ther Apher Dial 2009; 13: 404-412
• 48 Stutchfield BM. Simpson K. Wigmore SJ. Systematic review and meta-analysis of survival following extracorporeal liver support. Br J Surg 2011; 98: 623-631
• 49 Larsen FS. Schmidt LE. Bernsmeier C. et al. High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial. J Hepatol 2016; 64: 69-78
• 50 Arroyo V. Moreau R. Jalan R. et al. Acute-on-chronic liver failure: A new syndrome that will re-classify cirrhosis. J Hepatol 2015; 62: S131-43
• 51 Arroyo V andFernandez J. Pathophysiological basis of albumin use in cirrhosis. Ann Hepatol 2011; 10 (Suppl. 01) S6-14
• 52 Wong F. Nadim MK. Kellum JA. et al. Working Party proposal for a revised classification system of renal dysfunction in patients with cirrhosis. Gut 2011; 60: 702-709
• 53 Schachschal G. Morgera S. Kupferling S. et al. Emerging indications for MARS dialysis. Liver 2002; 22 (Suppl. 02) 63-68
• 54 Heemann U. Treichel U. Loock J. et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: a prospective, controlled study. Hepatology 2002; 36: 949-958
• 55 Schmidt LE. Wang LP. Hansen BA. et al. Systemic hemodynamic effects of treatment with the molecular adsorbents recirculating system in patients with hyperacute liver failure: a prospective controlled trial. Liver Transpl 2003; 9: 290-297
• 56 Sorkine P. Ben AbrahamR. Szold O. et al. Role of the molecular adsorbent recycling system (MARS) in the treatment of patients with acute exacerbation of chronic liver failure. Crit Care Med 2001; 29: 1332-1336
• 57 Dethloff T. Tofteng F. Frederiksen HJ. et al. Effect of Prometheus liver assist system on systemic hemodynamics in patients with cirrhosis: a randomized controlled study. World J Gastroenterol 2008; 14: 2065-2071
• 58 Sen S. Rose C. Ytrebo LM. et al. Effect of albumin dialysis on intracranial pressure increase in pigs with acute liver failure: a randomized study. Crit Care Med 2006; 34: 158-164
• 59 Blei AT. Albumin dialysis for the treatment of hepatic encephalopathy. Jour Gastroenterology and Hepatology 2004; 19: 224-228
• 60 Mitzner S. Loock J. Peszynski P. et al. Improvement in central nervous system functions during treatment of liver failure with albumin dialysis MARS--a review of clinical, biochemical, and electrophysiological data. Metab Brain Dis 2002; 17: 463-475
• 61 Schmidt LE. Svendsen LB. Sorensen VR. et al. Cerebral blood flow velocity increases during a single treatment with the molecular adsorbents recirculating system in patients with acute on chronic liver failure. Liver Transpl 2001; 7: 709-712
• 62 Stenbog P. Busk T. Larsen FS. Efficacy of liver assisting in patients with hepatic encephalopathy with special focus on plasma exchange. Metab Brain Dis 2013; 28: 333-335
• 63 Mitzner SR. Stange J. Klammt S. et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-286
• 64 Kribben A. Gerken G. Haag S. et al. Effects of fractionated plasma separation and adsorption on survival in patients with acute-on-chronic liver failure. Gastroenterology 2012; 142: 782-789.e3
• 65 Banares R. Nevens F. Larsen FS. et al. Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: the RELIEF trial. Hepatology 2013; 57: 1153-1162
• 66 Lee KC. Stadlbauer V. Jalan R. Extracorporeal liver support devices for listed patients. Liver Transpl 2016; 22: 839-848
• 67 Jalan R. Saliba F. Pavesi M. et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol 2014; 61: 1038-1047
• 68 Jalan R. Pavesi M. Saliba F. et al. The CLIF Consortium Acute Decompensation score (CLIF-C ADs) for prognosis of hospitalised cirrhotic patients without acute-on-chronic liver failure. J Hepatol 2015; 62: 831-840
• 69 Moreau R. Jalan R. Gines P. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 2013; 144: 1426-1437.e1-9
• 70 Kjaergard LL. Liu J. Als-Nielsen B. et al. Artificial and bioartificial support systems for acute and acute-on-chronic liver failure: a systematic review. JAMA 2003; 289: 217-222
• 71 Zheng Z. Li X. Li Z. et al. Artificial and bioartificial liver support systems for acute and acute-on-chronic hepatic failure: A meta-analysis and meta-regression. Exp Ther Med 2013; 6: 929-936
• 72 Shen Y. Wang XL. Wang B. et al. Survival Benefits with Artificial Liver Support System for Acute-on-Chronic Liver Failure: A Time Series-Based Meta-Analysis. Medicine (Baltimore) 2016; 95: e2506
• 73 Qin G. Shao JG. Wang B. et al. Artificial liver support system improves short- and long-term outcomes of patients with HBV-associated acute-on-chronic liver failure: a single-center experience. Medicine (Baltimore) 2014; 93: e338
• 74 Tsipotis E. Shuja A. Jaber BL. Albumin Dialysis for Liver Failure: A Systematic Review. Adv Chronic Kidney Dis 2015; 22: 382-390
• 75 Brass P. Hellmich M. Kolodziej L. et al. Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization. Cochrane Database Syst Rev 2015; 1
• 76 Hassanein T. Oliver D. Stange J. et al. Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs. Liver Int 2003; 23 (Suppl. 03) 61-65
• 77 Hessel FP. Economic evaluation of the artificial liver support system MARS in patients with acute-on-chronic liver failure. Cost Eff Resour Alloc 2006; 4: 16
• 78 Morgera S. Haase M. Rocktaschel J. et al. Intermittent high-permeability hemofiltration modulates inflammatory response in septic patients with multiorgan failure. Nephron Clin Pract 2003; 94: 75-80
• 79 Lee KC. Baker LA. Stanzani G. et al. Extracorporeal liver assist device to exchange albumin and remove endotoxin in acute liver failure: Results of a pivotal pre-clinical study. J Hepatol 2015; 63: 634-642
• 80 Al-Chalabi A. Matevossian E. Thaden AK. et al. Evaluation of the Hepa Wash(R) treatment in pigs with acute liver failure. BMC Gastroenterol 2013; 13: 83
• 81 Forni LG. Ricci Z. Ronco C. Extracorporeal renal replacement therapies in the treatment of sepsis: where are we?. Semin Nephrol 2015; 35: 55-63
• 82 Tomescu DR. Dima OS. Ungureanu D. et al. First report of cytokine removal using CytoSorb(R) in severe noninfectious inflammatory syndrome after liver transplantation. Int J Artif Organs 2016; 39: 136-140
• 83 Frimmel S. Schipper J. Henschel J. et al. First description of single-pass albumin dialysis combined with cytokine adsorption in fulminant liver failure and hemophagocytic syndrome resulting from generalized herpes simplex virus 1 infection. Liver Transpl 2014; 20: 1523-1524
• 84 Al-Chalabi A. Matevossian E. Thaden VAK. et al. Evaluation of the Hepa Wash(R) treatment in pigs with acute liver failure. BMC Gastroenterol 2013; 13: 83
• 85 Henschel B. Schmid R. Huber W. First clinical experience with a new type of albumin dialysis: the HepaWash® system. Crit Care 2015; 19 (Suppl. 01) 383
• 86 Assess Safety and Efficacy of ELAD (Extracorporeal Liver Assist System) in Subjects With Alcohol-Induced Liver Failure. (NCT01471028). ClinicalTrials.gov